EUVIMEDEUVIMED entdecken
Crossref

Carbon-11 Isotopic Labeling and PET Evaluation of Serodolin: A β-Arrestin-Biased Ligand with Antinociceptive Properties

Alexandre Hauwelle, Sébastien Goutal, Maxime Molins, Nicolas Tournier iD, Franck Suzenet iD, Séverine Morisset-Lopez iD, Davide Audisio iD, Fabien Caillé iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.6c00482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Alexandre Hauwelle und 7 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay , Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale Paris Saclay (BioMaps), OrsayF-91401, France. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Carbon Radioisotopes, Analgesics. Die Arbeit nennt 17 Literaturangaben. Gefördert von: CEA, European Union?s Horizon 2020 research and innovation program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Serodolin is a biased agonist of the 5-HT7 receptors that has demonstrated promising antinociceptive properties in preclinical models. To further support the development of this potential drug, we decided to use PET imaging to demonstrate in vivo the capacity of Serodolin to cross the blood–brain barrier and bind specifically in the brain. For that matter, Serodolin was isotopically radiolabeled with carbon-11 (β+, t1/2 = 20.4 min) using the Staudinger/aza-Wittig strategy and an azide precursor synthesized in 3 steps with an 18% yield. After optimization, automated radiosynthesis afforded [11C]Serodolin in 79 ± 4% decay-corrected radiochemical yield (n = 6) within 30 min. Quality control performed by analytical HPLC showed that ready-to-inject [11C]Serodolin was obtained with over 95% radiochemical and chemical purities and a molar activity of 55 ± 3 GBq/μmol (n = 6). Blood kinetics of [11C]Serodolin performed with and without coinjection of nonradioactive Serodolin (5 mg/kg) in healthy rats displayed a rapid distribution (1.25 min) and fast systemic clearance with no significant difference between the tracer and pharmacological doses. Brain PET imaging and kinetics in healthy rats showed a rapid accumulation of [11C]Serodolin (Cmax = 1.70 ± 0.35 standard uptake value at 3 min postinjection) and a widespread distribution throughout the brain parenchyma, whereas coinjection with nonradioactive Serodolin (5 mg/kg) resulted in a generalized and significant (p = 0.000012, two-way ANOVA) reduction of brain exposure (area under the curve (0–60) < 30%). These results demonstrate for the first time in vivo a reduced brain exposure under pharmacological coinjection, consistent with central target engagement of Serodolin, and encourage further development of this molecule as a potential antinociceptive drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyCarbon RadioisotopesAnalgesicsAnimalsRatsMaleIsotope LabelingBrainLigandsTissue DistributionBlood-Brain BarrierRats, Sprague-DawleyRadiopharmaceuticals

Stichwörter der Autor:innen

PET imagingcarbon-11isotopic labelingserodolin

Substanzen

Carbon RadioisotopesCarbon-11AnalgesicsLigandsRadiopharmaceuticals

Autor:innen und Institutionen

  • Université Paris-Saclay , Inserm, CNRS, CEA, Laboratoire d'Imagerie Biomédicale Multimodale Paris Saclay (BioMaps), OrsayF-91401, France.
  • Université Paris-Saclay, CEA, Service de Chimie Bio-Organique et Marquage, DMTS, Gif-Sur-YvetteF-91191, France.
  • Université d'Orléans , CNRS, ICOA, UMR 7311, Orléans45100, France.
  • Centre de Biophysique Moléculaire, Centre National de la Recherche Scientifique (CNRS), UPR 4301, Université d'Orléans, rue Charles Sadron, Orléans Cedex 245071, France.

ORCID-Profile: Nicolas Tournier, Franck Suzenet, Séverine Morisset-Lopez, Davide Audisio, Fabien Caillé

Förderung

  • CEA
  • European Union?s Horizon 2020 research and innovation program

Zitieren

APA

Hauwelle, A., Goutal, S., Molins, M., Tournier, N., Suzenet, F., Morisset-Lopez, S., Audisio, D., & Caillé, F. (2026). Carbon-11 Isotopic Labeling and PET Evaluation of Serodolin: A β-Arrestin-Biased Ligand with Antinociceptive Properties. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00482

Vancouver

Hauwelle A, Goutal S, Molins M, Tournier N, Suzenet F, Morisset-Lopez S, et al. Carbon-11 Isotopic Labeling and PET Evaluation of Serodolin: A β-Arrestin-Biased Ligand with Antinociceptive Properties. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00482

BibTeX
@article{Hauwelle2026,
  author = {Hauwelle, Alexandre and Goutal, Sébastien and Molins, Maxime and Tournier, Nicolas and Suzenet, Franck and Morisset-Lopez, Séverine and Audisio, Davide and Caillé, Fabien},
  title = {Carbon-11 Isotopic Labeling and PET Evaluation of Serodolin: A β-Arrestin-Biased Ligand with Antinociceptive Properties},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00482}
}
Kostenlos starten →